PMID- 23561899
OWN - NLM
STAT- MEDLINE
DCOM- 20131118
LR  - 20181202
IS  - 1776-2561 (Electronic)
IS  - 0761-8417 (Linking)
VI  - 69
IP  - 2
DP  - 2013 Apr
TI  - [Crizotinib: a targeted therapy in advanced ALK-positive non-small cell lung 
      cancer].
PG  - 111-6
LID - S0761-8417(13)00039-4 [pii]
LID - 10.1016/j.pneumo.2012.11.010 [doi]
AB  - Crizotinib is a small orally-administered ALK inhibitor for patients with 
      non-small cell lung cancer with EML4-ALK rearrangement (echinoderm 
      microtubule-associated protein-like 4 and anaplastic lymphoma kinase). This 
      fusion gene is detected with a break apart fluorescence in situ hybridization 
      (FISH) assay. Phase I to III trials have shown an interesting disease control 
      rate and acceptable tolerability. Crizotinib is available in France under 
      temporary use authorization. New potentially effective therapeutics in 
      ALK-positive NSCLC are being developed.
CI  - Copyright (c) 2013 Elsevier Masson SAS. All rights reserved.
FAU - Toffart, A-C
AU  - Toffart AC
AD  - UM Oncologie Thoracique, pole Cancerologie Medecine Aigue et Communautaire, 
      Centre Hospitalier Universitaire A.-Michallon, BP 217, 38043 Grenoble cedex 9, 
      France. AToffart@chu-grenoble.fr
FAU - Sakhri, L
AU  - Sakhri L
FAU - Moro-Sibilot, D
AU  - Moro-Sibilot D
LA  - fre
PT  - Journal Article
TT  - Crizotinib : une therapeutique ciblant le rearrangement EML4-ALK chez les 
      patients porteurs d'un cancer bronchique non a petites cellules metastatique.
DEP - 20130404
PL  - France
TA  - Rev Pneumol Clin
JT  - Revue de pneumologie clinique
JID - 8406312
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Drugs, Investigational)
RN  - 0 (EML1-ABL1 fusion protein, human)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyrazoles)
RN  - 0 (Pyridines)
RN  - 53AH36668S (Crizotinib)
SB  - IM
MH  - Adenocarcinoma/drug therapy/genetics/pathology
MH  - Administration, Oral
MH  - Antineoplastic Agents/*administration & dosage/adverse effects
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/*genetics/pathology
MH  - Clinical Trials as Topic
MH  - Crizotinib
MH  - Drugs, Investigational/*administration & dosage/adverse effects
MH  - France
MH  - Gene Rearrangement/genetics
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Lung Neoplasms/*drug therapy/*genetics/pathology
MH  - *Molecular Targeted Therapy
MH  - Neoplasm Staging
MH  - Oncogene Proteins, Fusion/*genetics
MH  - Protein Kinase Inhibitors/*administration & dosage/adverse effects
MH  - Pyrazoles/*administration & dosage/adverse effects
MH  - Pyridines/*administration & dosage/adverse effects
MH  - Tomography, X-Ray Computed
EDAT- 2013/04/09 06:00
MHDA- 2013/11/19 06:00
CRDT- 2013/04/09 06:00
PHST- 2012/07/17 00:00 [received]
PHST- 2012/11/20 00:00 [revised]
PHST- 2012/11/22 00:00 [accepted]
PHST- 2013/04/09 06:00 [entrez]
PHST- 2013/04/09 06:00 [pubmed]
PHST- 2013/11/19 06:00 [medline]
AID - S0761-8417(13)00039-4 [pii]
AID - 10.1016/j.pneumo.2012.11.010 [doi]
PST - ppublish
SO  - Rev Pneumol Clin. 2013 Apr;69(2):111-6. doi: 10.1016/j.pneumo.2012.11.010. Epub 
      2013 Apr 4.